Cutaneous T-cell Lymphoma

• FDA label_change · 2021-03-24
  FDA Approved: ISTODAX — Supplemental Application (Celgene Corporation)

  FDA approved a supplemental application for Istodax (romidepsin) to update its labeling, likely reflecting a new indication, safety, or othe…

• FDA label_change · 2020-01-13
  FDA Approved: VALCHLOR — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)

  FDA approves a supplemental application for VALCHLOR (mechlorethamine hydrochloride) to expand its labeling for the topical treatment of cut…

• FDA label_change · 2015-10-29
  FDA Approved: VALCHLOR — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)

  FDA approved a supplemental application for VALCHLOR (mechlorethamine hydrochloride), resulting in labeling updates for the product.

• FDA label_change · 2013-06-05
  FDA Approved: UVADEX — Supplemental Application (Therakos LLC)

  FDA approved a supplemental application for UVADEX (methoxsalen) submitted by Therakos LLC, updating the product's labeling for its use in p…

• FDA label_change · 2011-05-16
  FDA Approved: TARGRETIN — Supplemental Application (Bausch Health US, LLC)

  FDA approved a supplemental application for TARGRETIN (bexarotene) from Bausch Health US, LLC.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.